The use of medications for inflammatory bowel disease during pregnancy and nursing

Bibliography

• HANAUER SB, PRESENT DH: The state of the art in the management of inflammatory bowel disease.. Gastroenterol Disord. (2003) 3:81–92.
   PubMedGoogle Scholar
• BANKS BM, KORELITZ BI, ZETZEL L: The course of nonspecific ulcerative colitis: review of twenty years' experience and late results. Gastroenterology (1957) 32:983–1012.
   PubMed Web of Science ®Google Scholar
• LINDHAGEN T, BOHE M, VALENTIN Let al.: Fertility and outcome of pregnancy in patients operated on for Crohn's disease. Int. J. Colorectal Dis. (1986) 1:25–27.
   Google Scholar
• WILLOUGHBY CP, TRUELOVE SC: Ulcerative colitis and pregnancy. (1980) 21:469–474.
   Google Scholar
• MILLER JP: Inflammatory bowel disease in pregnancy: a review. J. R. Soc. Med. (1986) 79:221–225.
   PubMed Web of Science ®Google Scholar
• KHOSLA R, WILLOUGHBY CP, JEWELL DP: Crohn's disease and pregnancy. Gut (1984) 25:52–56.
   PubMed Web of Science ®Google Scholar
• MOGADAM M, KORELITZ BI, BAIOCCO PJ et al.: The course of inflammatory bowel disease during pregnancy and postpartum.. J. Gastroenterol (1981) 75:265–269.
   Web of Science ®Google Scholar
• ••This is one of the first papers to fullyexplore the issue of pregnancy in IBD.
   Google Scholar
• DONALDSON RM, JR: of medical problems in pregnancy-inflammatory bowel disease. N Engl. J. Med. (1985) 312:1616–1619.
   PubMed Web of Science ®Google Scholar
• BAIOCCO PJ, KORELITZ BI: The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J. Clin. Gastroenterol (1984) 6:211–216.
   PubMed Web of Science ®Google Scholar
• KORNFELD D, CNATTINGIUS S, EKBOM A: Pregnancy outcomes in women with inflammatory bowel disease-a population-based cohort study. Am. J. Obstet. GynecoL (1997) 177:942–946.
   PubMed Web of Science ®Google Scholar
• SCHADE RR, VAN THIEL DH, GAVALER JS: Chronic idiopathic ulcerative colitis. Pregnancy and fetal outcome. Dig. Dis. Sci. (1984) 29:614–619.
   PubMed Web of Science ®Google Scholar
• NORGARD B, FONAGER K, SORENSEN HT et al.: Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut (2003) 52:243–247.
   PubMed Web of Science ®Google Scholar
• ••This is a very large cohort studyusing a stable population exposed to AZA.
   Google Scholar
• MOGADAM M, DOBBINS WO III, AHMED SW et al.: Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology (1981) 80:72–76.
   PubMed Web of Science ®Google Scholar
• KORELITZ BI: Pregnancy, fertility, and inflammatory bowel disease. Am. J. Gastroenterol. (1985) 80:365–370.
   PubMed Web of Science ®Google Scholar
• KANE S: Inflammatory bowel disease in pregnancy. Gastroenterol Clin. North Am. (2003) 32:323–340.
   PubMed Web of Science ®Google Scholar
• LOFTUS EV Jr, KANE SV, BJORKMAN D: Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment. PharmacoL Ther. (2004) 19:179–189.
   PubMed Web of Science ®Google Scholar
• HENSLEIGH PA, KAUFFMAN RE: Maternal absorption and placental transfer of sulfasalazine. Am. J. Obstet. GynecoL (1977) 127:443–444.
   PubMed Web of Science ®Google Scholar
• BELL CM, HABAL FM: Safety of topical 5-aminosalicylic acid in pregnancy.. J. Gastroenterol. (1997) 92:2201–2202.
   Web of Science ®Google Scholar
• DIAV-CITRIN O, PARK YH, VEERASUNTHARAM G et al.: The of mesalamine in human pregnancy: prospective controlled cohort study. Gastroenterology (1998) 114:23–28.
   PubMed Web of Science ®Google Scholar
• ••This is one of the very fewprospective studies using a medication during pregnancy.
   Google Scholar
• HABAL FM, HUT G, GREENBERG GR: Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology (1993) 105:1057–1060.
   PubMed Web of Science ®Google Scholar
• MARTEAU P, TENNENBAUM R, COSNES J et al.: Fetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules. Aliment. Pharmacol Ther. (1998) 12:1101–1108.
   PubMed Web of Science ®Google Scholar
• ••This is another controlled studylooking at outcomes in pregnancy with drug exposure.
   Google Scholar
• FERRERO S, RAGNI N: Inflammatory bowel disease: management issues during pregnancy. Arch. GynecoL Obstet. (2004) 270:79–85.
   PubMedGoogle Scholar
• ALSTEAD EM, NELSON-PIERCY C: Inflammatory bowel disease in pregnancy. Gut (2003) 52:159–161.
   PubMed Web of Science ®Google Scholar
• MOSKOVITZ DN, BODIAN C, CHAPMAN ML et al.: The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am. J. Gastroenterol (2004) 99:656–661.
   PubMed Web of Science ®Google Scholar
• COLOMBEL JF, BRABANT G, GUBLER MC et al.: Renal insufficiency in infant: side effect of prenatal exposure to mesalazine? Lancet (1994) 344:620–621.
   Google Scholar
• HERNANDEZ-DIAZ S, WERLER MM, MITCHELL AA et al.: Folic acid antagonists during pregnancy and the risk of birth defects. N Engl. J. Med. (2000) 343:1608–1614.
   PubMed Web of Science ®Google Scholar
• WARRELL DW, TAYLOR R: Outcome for the fetus of mothers receiving prednisolone during pregnancy. Lancet (1968) 1:117–118.
   PubMed Web of Science ®Google Scholar
• BEITINS IZ, BAYARD F, MIGEON CJ et al.: The transplacental passage of prednisone and prednisolone in pregnancy near term. J. Pediatr. (1972) 81:936–945.
   PubMed Web of Science ®Google Scholar
• ROSENKRANTZ JG, GITHENS JH, KELLUM DL et al.: Azathioprine (Imuran) and pregnancy. Am. J. Obstet. Gynecol (1967) 97:387–394.
   PubMed Web of Science ®Google Scholar
• SAARIKOSKI S, SEPPALA M: Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am. J. Obstet. Gynecol (1973) 115:1100–1106.
   PubMed Web of Science ®Google Scholar
• DUBINSKY MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology efficacy, and safety. Clin Gastroenterol Repaid. (2004) 2:731–743.
   PubMed Web of Science ®Google Scholar
• MATALON ST, ORNOY A, LISHNER M: Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs. (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta). Reprod. Toxicol. (2004) 18:219–230.
   PubMed Web of Science ®Google Scholar
• PRESENT DH, MELTZER SJ, BI et al.: 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann. Intern. Med. (1989) 111:641–649.
   PubMed Web of Science ®Google Scholar
• PENN I, MAKOWSKI E, STARZL TE et al.: Parenthood in renal homograft recipients. /AMA (1971) 216:1755–1761.
   PubMed Web of Science ®Google Scholar
• GILLIBRAND PN: Systemic lupus erythematosus in pregnancy treated with azathioprine. Proc. R. Soc. Med. (1966) 59:834.
   PubMedGoogle Scholar
• NORGARD B, PEDERSEN L, SORENSEN HT et al.: Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment. Pharmacol Ther. (2003) 17:827–834.
   PubMed Web of Science ®Google Scholar
• FRANCELLA A, DYAN A, PRESENT DH et al: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology (2003) 124:9–17.
   PubMed Web of Science ®Google Scholar
• ••This is the largest study to date to examine use of 6-MP for IBD in pregnancy.
   Google Scholar
• RAMSEY-GOLDMAN R, SCHILLING E: Immunosuppressive drug use during pregnancy. Rheum. Dis. Clin. North Am. (1997) 23:149–167.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review ofimmunosuppressive medications used in pregnancy.
   Google Scholar
• BERTSCHINGER P, HIMMELMANN A. FOLLATH F et al.: Cyclosporin treatment of severe ulcerative colitis during pregnancy. Am. J. Gastroenterol (1995) 90:330.
   Google Scholar
• KORNBLUTH A. REDDY D: Management and outcome of severe colitis in pregnancy. Am. J. Gastroenterol (2002) 97:P705.
   Web of Science ®Google Scholar
• GOLDENBERG M, BIDER D, OELSNER G et al.: Methotrexate therapy of tubal pregnancy. Hum. &prod. (1993) 8:660–666.
   PubMed Web of Science ®Google Scholar
• KATZ JA, ANTONI C, GR et al.: Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol (2004) 99:2385–2392.
   PubMed Web of Science ®Google Scholar
• BURTIN P, TADDIO A, KOREN G et al: Safety of metronidazole in pregnancy: a meta-analysis. Am. J. Obstet. Gynecol (1995) 172:525–529.
   PubMed Web of Science ®Google Scholar
• DIAV-CITRIN O, SHECHTMAN S, ORNOY A et al.: Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology (2001) 63:186–192.
   PubMedGoogle Scholar
• PIPER JM, MITCHEL EF, RAY WA: Prenatal use of metronidazole and birth defects: no association. Obstet. GynecoL (1993) 82:348–352.
   PubMed Web of Science ®Google Scholar
• CARO-PATON T, CARVAJAL A, RODRIGUEZ-PINELLA E et al: Is metronidazole teratogenic? A meta-analysis. Br. J. Clin. Pharmacol (1997) 44:179–182.
   PubMed Web of Science ®Google Scholar
• LOEBSTEIN R, ADDIS k HO E et al: Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study.. Agents Chemother. (1998) 42:1336–1339.
   PubMed Web of Science ®Google Scholar
• SCHAEFER C, AMOURA-ELEFANT E, VIAL T et al.: Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur. j Obstet. Gynecol &prod. Biol. (1996) 69:83–89.
   Google Scholar
• EINARSON A, MASTROIACOVO P, ARNON J et al: Prospective, controlled, multi-centre study of loperamide in pregnancy. Can. J. Gastroenterol (2000) 3:185–187.
   Google Scholar
• GATTUSO JM, KAMM MA: Adverse effects of drugs used in the management of constipation and diarrhoea. Drug Saf (1994) 1:47–65.
   Google Scholar
• KANE S, LEMIEUX N: The role of breastfeeding in postpartum disease activity in women with inflammatory bowel disease. Am. J. Gastroenterol (2005) 100:102–105.
   PubMed Web of Science ®Google Scholar
• NELIS GF: Diarrhoea due to 5-aminosalicyclic acid in breast milk. (1989) 1(8634):383.
   Google Scholar
• KLOTZ U, HARINGS-KAIM k Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet (1993) 342:618–619.
   PubMed Web of Science ®Google Scholar
• NYBERG G, HALJAMAE U, I et al: Breastfeeding during treatment with cyclosporin. Transplantation (1998) 65:253–255.
   PubMed Web of Science ®Google Scholar
• ••A study from a large transplant database ofbreastfeeding and cyclosporin use.
   Google Scholar
• MUNOZ-FLORES-THIAGARAJAN KD, EASTERLING T, BOND EF et al: Breastfeeding by a cyclosporin-treated mother. Obstet. Gynecol (2001) 97:816–818.
   PubMed Web of Science ®Google Scholar
• OST L, WETTRELL G, RANE A et al.: Prednisolone excretion in human milk. Pediatr. (1985) 106:1008–1011.
   Web of Science ®Google Scholar
• KANE S: Breastfeeding and IBD: safety and management issues. Inflammatory Bowel Disease Monitor. (2004) 6:50–52.
   Google Scholar